[go: up one dir, main page]

CL2018003123A1 - Terapia de combinación para el tratamiento del cáncer - Google Patents

Terapia de combinación para el tratamiento del cáncer

Info

Publication number
CL2018003123A1
CL2018003123A1 CL2018003123A CL2018003123A CL2018003123A1 CL 2018003123 A1 CL2018003123 A1 CL 2018003123A1 CL 2018003123 A CL2018003123 A CL 2018003123A CL 2018003123 A CL2018003123 A CL 2018003123A CL 2018003123 A1 CL2018003123 A1 CL 2018003123A1
Authority
CL
Chile
Prior art keywords
combination therapy
cancer treatment
cancer
treatment
therapy
Prior art date
Application number
CL2018003123A
Other languages
English (en)
Inventor
Jeffery L Keene
Dennis P Riley
Robert A Beardsley
Jr Douglas R Spitz
Melissa A Fath
Original Assignee
Galera Labs Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galera Labs Llc filed Critical Galera Labs Llc
Publication of CL2018003123A1 publication Critical patent/CL2018003123A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

TERAPIA DE COMBINACIÓN PARA EL TRATAMIENTO DEL CÁNCER
CL2018003123A 2016-05-03 2018-10-31 Terapia de combinación para el tratamiento del cáncer CL2018003123A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662331253P 2016-05-03 2016-05-03

Publications (1)

Publication Number Publication Date
CL2018003123A1 true CL2018003123A1 (es) 2019-05-03

Family

ID=60203338

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003123A CL2018003123A1 (es) 2016-05-03 2018-10-31 Terapia de combinación para el tratamiento del cáncer

Country Status (14)

Country Link
US (1) US12220420B2 (es)
EP (1) EP3452060A4 (es)
JP (2) JP2019514962A (es)
KR (2) KR20180132939A (es)
CN (1) CN109414454A (es)
AU (2) AU2017260425B2 (es)
BR (1) BR112018072560A2 (es)
CA (1) CA3022699A1 (es)
CL (1) CL2018003123A1 (es)
EA (1) EA201892510A3 (es)
IL (3) IL300085A (es)
MX (1) MX393974B (es)
SG (2) SG10202106462TA (es)
WO (1) WO2017192740A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2056675B1 (en) 2006-10-12 2019-01-09 Galera Labs, LLC Methods of treating oral mucositis
WO2013048965A1 (en) 2011-09-26 2013-04-04 Galera Therapeutics, Llc Methods for treatment of diseases
UA126788C2 (uk) 2015-08-11 2023-02-08 Ґалера Лебз, Елелсі Комплексні сполуки, що містять макроциклічне кільце пентаази, які мають пероральну біодоступність
US12220420B2 (en) 2016-05-03 2025-02-11 Galera Labs, Llc Combination therapy for cancer treatment
EP3763704A1 (en) 2016-05-03 2021-01-13 Bayer Pharma Aktiengesellschaft Aromatic sulfonamide derivatives
AU2017318718B2 (en) 2016-09-01 2023-06-29 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
US11246950B2 (en) 2017-04-13 2022-02-15 Galera Labs, Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex
WO2019098288A1 (ja) * 2017-11-15 2019-05-23 学校法人 慶應義塾 抗腫瘍剤及び配合剤
WO2019104579A1 (en) * 2017-11-30 2019-06-06 SHIEH, Darbin Method for predicting and modulating susceptibility of cancer cell to programmed cell death
GB201800733D0 (en) * 2018-01-17 2018-02-28 Cambridge Entpr Ltd Cancer
JP7716680B2 (ja) * 2018-01-31 2025-08-01 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法
AU2019215032A1 (en) * 2018-01-31 2020-09-10 Board Of Regents Of The University Of Texas System Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
US20210221889A1 (en) * 2018-06-08 2021-07-22 Atomic Energy Of Canada Limited/Ènergie Atomique Du Canada Limitèe Use of a checkpoint inhibitor in combination with ultralow dose whole body irradiation
CN109620836B (zh) * 2018-12-24 2021-05-18 陕西科技大学 一种具有抗乳腺癌作用的复方药物组合物及其用途和基于此组合物的药物
WO2021050490A1 (en) * 2019-09-13 2021-03-18 The Trustees Of Columbia University In The City Of New York Methods of enhancing radiotherapy using ferroptosis inducers as radiosensitizers
IL291989A (en) * 2019-10-10 2022-06-01 Galera Labs Llc Production method for an aqueous formulation of a manganese-containing coordination complex, formulation and treatment method
US12133846B2 (en) 2019-10-15 2024-11-05 Wayne State University Electrophilic androgen receptor (AR) antagonists for AR downregulation and ferroptosis induction in cancer cells
WO2021247714A1 (en) 2020-06-02 2021-12-09 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and hormone therapy agent
US20230265108A1 (en) * 2020-07-29 2023-08-24 University Of Kentucky Research Foundation Gold(iii) compounds and cancer cell-selective modulation of mitochondrial respiration and metabolism
WO2024026273A1 (en) * 2022-07-25 2024-02-01 Galera Labs, Llc Therapy for reduced ototoxicity from chemotherapeutic agent with pentaaza macrocyclic ring complex
US20240415869A1 (en) * 2023-06-15 2024-12-19 Novocure Gmbh Compositions, systems, and methods for treating cancer using tumor treating fields (ttfields) and thioredoxin/glutathione inhibitors

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001212A (en) 1973-10-03 1977-01-04 E. I. Du Pont De Nemours And Company Macrocyclic polyamines
US3930867A (en) 1974-01-07 1976-01-06 E. I. Du Pont De Nemours And Company Macrocyclic polyamines as sensitizers for silver halide emulsions
JPS61226751A (ja) 1985-03-30 1986-10-08 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料用処理液及びその処理方法
US5096724A (en) 1988-06-03 1992-03-17 Aquanautics Corporation Methods, compositions, and systems for ligand extraction
GB9001245D0 (en) 1990-01-19 1990-03-21 Salutar Inc Compounds
DE69224839T2 (de) 1991-07-19 1998-10-08 Monsanto Co Mangan-Komplexe mit Stickstoff enthaltenden makrozyklischen Liganden, wirksam als Superoxiddismutasekatalysatoren.
CA2072934C (en) 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
CA2188530A1 (en) 1994-04-22 1995-11-02 John Charles Alexander Diagnostic image analysis with metal complexes
US6245758B1 (en) 1994-05-13 2001-06-12 Michael K. Stern Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
JPH0840941A (ja) 1994-07-29 1996-02-13 Kanegafuchi Chem Ind Co Ltd 炎症性腸疾患治療製剤
US6525041B1 (en) 1995-06-06 2003-02-25 Pharmacia Corporation Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
JPH11511168A (ja) 1995-08-17 1999-09-28 モンサント カンパニー 窒素含有大環状リガンドの金属錯体の生体分子結合体を使用する診断造影検査方法
AU6722496A (en) 1995-08-17 1997-03-12 Monsanto Company Methods of diagnostic image analysis using metal complexes of nitrogen-containing macrocyclic ligands
US6180620B1 (en) 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US20060270639A1 (en) 1997-06-20 2006-11-30 Daniela Salvemini Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
US20020128248A1 (en) 1997-06-20 2002-09-12 Metaphore Pharmaceuticals, Inc SODm therapy for prevention and/or treatment of inflammatory disease
US20050171198A1 (en) 1997-06-20 2005-08-04 Metaphore Pharmaceuticals, Inc. SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
JP2991172B2 (ja) 1997-10-24 1999-12-20 日本電気株式会社 半導体装置
CA2309154C (en) 1997-11-03 2010-02-16 Duke University Substituted porphyrins
GB9817845D0 (en) 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
US6040330A (en) 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
AU5048400A (en) 1999-05-27 2000-12-18 Monsanto Company Biomaterials modified with superoxide dismutase mimics
US6448239B1 (en) 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
EP1194150A4 (en) 1999-06-23 2003-06-11 Eric F Bernstein USE OF NITROXIDES TO Heal Wounds And To Prevent Radiation Damage To Skin
US6552010B1 (en) 1999-11-12 2003-04-22 Genelabs Technologies, Inc. Treatment of SLE with dehydroepiandrosterone
EP2343047B2 (en) 2000-02-08 2021-03-17 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
DE50013843D1 (de) 2000-08-29 2007-01-18 Mepha Ag Arzneimittel zur behandlung von darmerkrankungen
US7166910B2 (en) 2000-11-28 2007-01-23 Knowles Electronics Llc Miniature silicon condenser microphone
US20020072512A1 (en) 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
US20050175580A1 (en) 2001-01-05 2005-08-11 Daniela Salvemini Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
ATE439134T1 (de) 2001-01-19 2009-08-15 Nat Jewish Med & Res Center Medikament zum schutz in der radiotherapie
EP1405066B1 (en) 2001-03-02 2015-06-17 Galera Therapeutics LLC Chromatography of metal complexes
US20040137638A1 (en) 2002-03-04 2004-07-15 Slomczynska Urszula J. Chromatography of metal complexes
WO2002100395A1 (en) 2001-06-08 2002-12-19 Genzyme Corporation Bismuth salts of anti-oxidants and radical scavengers for prevention and treatment of mucous membrane ulcers
NZ533164A (en) 2001-11-01 2008-09-26 Uab Research Foundation Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
AU2003229923A1 (en) 2002-04-16 2003-11-03 Isis Innovation Limited Curcumin for the prevention and/or treatment of tissue damage
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
US6781231B2 (en) 2002-09-10 2004-08-24 Knowles Electronics Llc Microelectromechanical system package with environmental and interference shield
US6798047B1 (en) 2002-12-26 2004-09-28 Amkor Technology, Inc. Pre-molded leadframe
WO2005042718A2 (en) 2003-10-31 2005-05-12 Metaphore Pharmaceuticals, Inc. Compositions and methods for treating, preventing, reversing and inhibiting pain
FR2863892B1 (fr) 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
US7510710B2 (en) 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
EA010834B1 (ru) 2004-03-29 2008-12-30 Инотек Фармасьютикалз Корпорейшн Пиридилзамещённые порфириновые соединения и способы их применения
US7262498B2 (en) 2004-10-19 2007-08-28 Hewlett-Packard Development Company, L.P. Assembly with a ring and bonding pads formed of a same material on a substrate
US20070148154A1 (en) 2004-12-17 2007-06-28 Universite Rene Descartes (Paris V) Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs
US20120301403A1 (en) 2007-06-21 2012-11-29 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
WO2006083508A2 (en) 2005-01-10 2006-08-10 Metaphore Pharmaceuticals Inc. Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
AU2006230292A1 (en) 2005-03-31 2006-10-05 Schering Corporation Spirocyclic thrombin receptor antagonists
CN2870352Y (zh) 2005-12-23 2007-02-14 瑞声声学科技(深圳)有限公司 微机电系统传声器扣合式封装结构
WO2008033466A2 (en) 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
EP2056675B1 (en) 2006-10-12 2019-01-09 Galera Labs, LLC Methods of treating oral mucositis
TWI333264B (en) 2007-01-10 2010-11-11 Advanced Semiconductor Eng Packaging structure and method of mems microphone
WO2009065059A2 (en) 2007-11-14 2009-05-22 Kereos, Inc. Super-oxide dismutase mimetics
CN101969926A (zh) 2008-02-29 2011-02-09 赛多仕有限公司 拓扑替康即用溶液
US20090257979A1 (en) 2008-04-15 2009-10-15 Intermune, Inc. Novel Inhibitors of Hepatitis C Virus Replication
ES2530462T3 (es) * 2008-05-22 2015-03-03 Galera Therapeutics Llc Combinación terapia antitumoral
PL2349245T3 (pl) * 2008-10-29 2017-07-31 Istituto Superiore di Sanità Leczenie utajonego zakażenia wirusem hiv-1 za pomocą auranofiny lub tritlenku diarsenu
WO2011113019A2 (en) 2010-03-12 2011-09-15 Abbott Biotherapeutics Corp. Ctla4 proteins and their uses
US20120207687A1 (en) 2011-01-14 2012-08-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Topical formulations of targeted nitroxide agents
WO2013048965A1 (en) * 2011-09-26 2013-04-04 Galera Therapeutics, Llc Methods for treatment of diseases
US9238659B2 (en) 2012-11-19 2016-01-19 The University Of Hong Kong Method of using binuclear gold (I) compounds for cancer treatment
FR3030240B1 (fr) 2014-12-23 2017-07-28 Oreal Procede de traitement des fibres keratiniques avec une composition comprenant un acide amine
UA126788C2 (uk) 2015-08-11 2023-02-08 Ґалера Лебз, Елелсі Комплексні сполуки, що містять макроциклічне кільце пентаази, які мають пероральну біодоступність
WO2017025496A1 (en) 2015-08-12 2017-02-16 Bayer Pharma Aktiengesellschaft Pharmaceutical combination for the treatment of cancer
US12220420B2 (en) 2016-05-03 2025-02-11 Galera Labs, Llc Combination therapy for cancer treatment
AU2017318718B2 (en) 2016-09-01 2023-06-29 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
US20190350867A1 (en) 2016-12-27 2019-11-21 Soon Kap Hahn Prevention of local tumor recurrence following surgery using sustained and/or delayed release of medicaments contained in micro-particles
CA3053779A1 (en) 2017-02-15 2018-08-23 Galera Labs, Llc Pentaaza macrocyclic ring complexes for local intestinal delivery
US11246950B2 (en) 2017-04-13 2022-02-15 Galera Labs, Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
AU2019215032A1 (en) 2018-01-31 2020-09-10 Board Of Regents Of The University Of Texas System Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
WO2024026273A1 (en) 2022-07-25 2024-02-01 Galera Labs, Llc Therapy for reduced ototoxicity from chemotherapeutic agent with pentaaza macrocyclic ring complex

Also Published As

Publication number Publication date
CN109414454A (zh) 2019-03-01
MX393974B (es) 2025-03-24
EA201892510A2 (ru) 2019-06-28
JP2023036950A (ja) 2023-03-14
CA3022699A1 (en) 2017-11-09
AU2017260425A1 (en) 2018-11-22
KR20180132939A (ko) 2018-12-12
EA201892510A3 (ru) 2019-09-30
IL262661A (en) 2018-12-31
SG11201809606YA (en) 2018-11-29
US12220420B2 (en) 2025-02-11
EP3452060A4 (en) 2020-01-01
EP3452060A2 (en) 2019-03-13
AU2017260425B2 (en) 2023-04-06
BR112018072560A2 (pt) 2019-02-19
WO2017192740A2 (en) 2017-11-09
MX2018013354A (es) 2019-02-20
AU2023204318A1 (en) 2023-07-27
IL300085A (en) 2023-03-01
JP2019514962A (ja) 2019-06-06
IL290149A (en) 2022-03-01
US20190151331A1 (en) 2019-05-23
IL262661B (en) 2022-03-01
KR20230075528A (ko) 2023-05-31
SG10202106462TA (en) 2021-07-29

Similar Documents

Publication Publication Date Title
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
ECSP17073743A (es) Moduladores de k-ras
MX394062B (es) Métodos para el tratamiento del cáncer ovárico.
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
EP3651772A4 (en) ANTI-CANCER POLYTHERAPY
IL249065A0 (en) Combination therapies for the treatment of cancer
LT3283527T (lt) Kompleksinė terapija vėžio gydymui
PL3580211T3 (pl) 2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
IL258521B1 (en) Combination therapy for the treatment of cancer
ECSP17015977A (es) Terapia de combinacion
IL284875A (en) Lasofoxifene treatment of breast cancer
EP3474854A4 (en) DRUG ASSOCIATIONS FOR THE TREATMENT OF CANCER
MX2018010993A (es) Derivados de icariina e icaritina.
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
MX2019009304A (es) Tratamiento para el cancer.
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
UY36286A (es) Tratamientos médicos basados en anamorelina
EP3413927A4 (en) CANCER THERAPY
HUE053648T2 (hu) Gyógyászati kombinációk rák kezelésére
EP3576791A4 (en) CALRETICULIN-MEDIATION CANCER TREATMENT
IL281845A (en) Combination therapy for the treatment of cancer
LT3352857T (lt) T-dm1 atsparių, vėžiu sergančių pacientų gydymas junginiu syd985
DK3407909T5 (da) Cancerbehandling